Amgen Inc. (AMGN) is a biotechnology company that has long been considered a bellwether in the healthcare sector. However, a closer look at the company's financial metrics raises some concerning questions about the quality of its earnings. Over the past year, AMGN's net income has grown from $4.2B in 2025Q1 to $5.2B in 2025Q4, a 23.8% increase. However, its operating cash flow over the same period has only grown from $2.0B to $2.1B, a mere 5.0% increase. This disconnect between the rapid growth in net income and the sluggish growth in cash flow is a red flag for earnings quality. It suggests that AMGN's profits may be boosted by accounting maneuvers rather than reflecting the underlying cash-generating power of the business. AMGN's accrual ratio, calculated as (net income - operating cash flow) / total assets, has widened from 0.52 in 2025Q1 to 0.69 in 2025Q4. This sharp increase in the accrual ratio indicates that AMGN's earnings are becoming increasingly disconnected from its actual cash flow, a classic sign of earnings manipulation. High accruals often precede earnings disappointments and balance sheet deterioration. Given these concerning trends in AMGN's earnings quality, I believe investors should approach the stock with caution. The company's profits may be less sustainable than they appear, and there is a risk of future earnings revisions or write-downs that could undermine shareholder value.

Research these companies